CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-β or No Disease Modifying Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05028634
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:51.815748+00:00
Published At: 2025-01-22T00:00:00+00:00
Record Updated At: 2025-02-11
Results Posted At: 2025-01-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Sclerosis", "Multiple Sclerosis, Relapsing-Remitting"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-02-11"
protocolSection.identificationModule.nctId: "NCT05028634"
protocolSection.identificationModule.officialTitle: "A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-\u03b2 or No Disease Modifying Therapy"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-01-22"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.